Trial Profile
A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Capecitabine; Docetaxel; Eribulin; Gemcitabine; Paclitaxel; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms PRECIOUS
- 06 Jun 2023 Results of updated overall survival at the median follow-up of 27.4 months presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 01 Sep 2022 Status changed from active, no longer recruiting to completed.
- 01 Sep 2022 Primary endpoint (Progression-free survival (assessed by investigators)) has been met, according to Results published in the Cancer Science.